1. Global Portfolio of Antimalarial Medicines
Translational
Product development
Access
Human volunteers
Patient exploratory
Patient confirmatory
Regulatory review
Preclinical
Approved/ERP
SAR121
Sanofi/MMV
P218
Janssen/MMV
AQ13
Immtech
Artefenomel/
Ferroquine
Sanofi/MMV
Dihydroartemisinin- piperaquine
dispersible
Alfasigma/MMV
Arterolane-
piperaquine
Sun Pharma ▲
Artemether-
lumefantrine
Various Manufacturers
Artesunate-
amodiaquine
Various Manufacturers/MMV 3 6 1
GSK701
GSK
SJ733
Kentucky/Eisai/MMV
Sevuparin
Modus Therapeutics
Ganaplacide/
Lumefantrine
Novartis/MMV
Co-trimoxazole
ITM Antwerp
Artesunate-
mefloquine
Cipla/MMV
Sulfadoxine-
pyrimethamine+
Amodiaquine dispersible S Kant/MMV
Artemether-
lumefantrine
Dispersible
Various Manufacturers/MMV 2
NPC1161B
Mississippi
ACT
Actelion
MMV048
MMV
Cipargamin
Novartis/MMV
Artemisinin-
naphthoquine
Kunming Pharma Co ▲
Sulfadoxine-
pyrimethamine+
amodiaquine
Fosun (Guilin)/MMV
Artesunate
for Injection
Fosun (Guilin)/ MMV 7
MK4815
Merck
CDRI 9778
Ipca
Rosiglitazone adjunct therapy Manhica, Toronto, Barcelona
DSM265
Takeda/MMV
Artemether sub-lingual spray
MRC/Suda 3
Rectal artesunate
Cipla/MMV
Dihydroartemisinin- piperaquine
Various manufacturers/ MMV 8
MMV253
Zydus Cadila/MMV
M5717
Merck KGaA /MMV
Imatinib
HuLow, Purdue, Turin, Sassari and Hue
Fosmidomycin Piperaquine
DMG Deutsche Malaria GmbH
Artemisinin-piperaquine
Artepharm
Rectal artesunate
Strides Pharma/ MMV 4 9
Pyronaridine-
Artesunate Shin Poong/MMV
SC83288
Heidelberg University
DM1157
DesignMedix
Methylene Blue/ amodiaquine
Heidelberg
Tafenoquine paediatric GSK/MMV
Artesunate-
amodiaquine
Sanofi
Tafenoquine
GSK/MMV 5 10
Isoxazolines
Calibr TropIQ
Pyronaridine-
artesunate granules
Shin Poong/MMV
Tafenoquine
60P/US Army 5 11
MMV370
MMV371
MMV
Artesunate
for Injection
Ipca/MMV
MMV052
MMV
Footnotes: Included in MMV portfolio after product approval and/or development. DNDi and partners completed development and registration of ASMQ and ASAQ. │ Global Fund Expert Review Panel (ERP) reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing. │ WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers. │ Paediatric formulation.

2. Footnotes: Global Portfolio
Target Product Profiles and Target Candidate Profiles
MMV has defined Target Product Profiles and Target Candidate Profiles for medicines to support the eradication campaign.
Burrows JN et al., New developments in anti‑malarial target candidate and product profiles et al. Malar J (2017) 16:26 updates the previous profiles in Burrows J et al.; Malaria Journal :187
Target Product Profiles
indicated by bars at the bottom of each compound box
Target Candidate Profiles
activities for each individual molecule, indicated by symbols added to each compound in the translational portfolio
Burrows Burrows
et al., 2013 et al., 2017
Asexual blood stages (TCP-1,2) TCP-1
Relapse prevention (TCP-3a) TCP-3
Transmission reduction (TCP-3b) TCP-5,6
Chemoprotection (TCP- 4) TCP-4
3-day cure, artemisinin-based combination therapies
Uncomplicated malaria treatments aiming at a new single-exposure radical cure (SERC) TPP-1
Severe malaria treatment / pre-referral intervention
Intermittent/seasonal malaria chemoprevention
Products targeting prevention of relapse for P. vivax
Single-exposure chemoprotection (SEC) TPP-2
Footnote for Generic names on Global Portfolio
1. First approval: Novartis (Brand name: Coartem®). Generics by Ajanta, Cipla, Ipca, Strides Pharma, Macleods, Mylan  
First approval: Novartis (Brand name: Coartem® Dispersible). Generics by Ajanta; Cipla; Strides Pharma; Ipca
Brand name: Artesun®
First approval: Alfasigma (Brand name: Eurartesim®). Generic by Fosun (ERP only)
Brand name: Pyramax® tablets and granules
First approval fixed-dose combination: Sanofi/DNDi (Brand name: ASAQ Winthrop). Generics by Ajanta, Cipla, Fosun, Ipca, Strides Pharma
Brand name: SPAQ-COTM
100mg Artesunate Rectocaps
ArtecapTM
Brand names: Kozenis/Krintafel (Trademarks owned or licensed by GSK)
Brand names: ARAKODATM/KODATEF
Additional Symbols on Global Portfolio
Brought into portfolio after approval; collaborations with DNDi
No progress report in the last two years
Global Fund Expert Review Panel (ERP) reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing.
Paediatric formulation
WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers.
Approved in several countries but not approved by WHO pre-qualification nor regulatory bodies who are ICH members or observers ▲